Humacyte, Inc. (HUMA) News
Follow Humacyte, Inc. (HUMA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Humacyte Q3 Results Expected November 10; EPS Estimate at $(0.10)
Humacyte is scheduled to report Q3'26 results before the market opens on November 10. Revenue is estimated at $766,000, with EPS expected at $(0.10).
EQUITY | Nov 09, 2026, 12:01 PM UTC
M
Humacyte to Report Third-Quarter Results and Provide Business Update November 10
Humacyte said it will release financial results for the three months ended in its third quarter of 2026 and provide a business update on November 10.
EQUITY | Nov 02, 2026, 01:02 PM UTC
L
Humacyte Phase 3 V012 results accepted for ASN Kidney Week presentation
Results for the ATEV trial in women requiring hemodialysis access were accepted for a late-breaking session at ASN Kidney Week 2026.
EQUITY | Oct 12, 2026, 12:00 PM UTC
L
Humacyte appoints Scott Coward and Paul Kuznik to its Board
Humacyte appointed Scott Coward and Paul Kuznik to its Board, with Coward joining the Audit Committee and Kuznik joining the Commercial Committee.Original SEC Filing: Humacyte, Inc. [ HUMA ] - 8-K - Sep. 28, 2026This is
REGULATION | Sep 28, 2026, 08:17 PM UTC
L
Humacyte, Inc. (HUMA) Adds Scott Coward and Paul Kuznik to Board
Humacyte appointed Scott Coward and Paul Kuznik to its Board of Directors, adding commercialization, governance and vascular device expertise.Material DetailsContext by AI AnalystThis is mid-cycle governance/commercial b
NEWS | Sep 28, 2026, 12:01 PM UTC
L
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. NASDAQ:HUMA, a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today an
NEWS | Sep 28, 2026, 12:01 PM UTC
L
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. NASDAQ:HUMA, a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today an
GEOPOLITICS | Sep 10, 2026, 12:04 PM UTC
L
HUMA - Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
HUMA - Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 10, 2026, 12:00 PM UTC
M
Humacyte gets FDA authorization to extend Symvess shelf life to 36 months
FDA authorized extending Symvess expiration dating from 18 months to 36 months. Humacyte says the extended shelf life is supported by additional stability data showing Symvess meets established quality specifications thr
REGULATION | Sep 09, 2026, 12:01 PM UTC
M
Humacyte plans supplemental BLA for atev dialysis access
Humacyte says it plans to file a supplemental BLA with the FDA for atev in dialysis access in November 2026, seeking a second approved indication backed by three phase 3 studies.
REGULATION | Aug 24, 2026, 12:00 PM UTC
M
Humacyte plans ATEV supplemental BLA filing for dialysis access
Humacyte says it plans a supplemental BLA filing for ATEV in dialysis access following FDA discussions.
REGULATION | Aug 24, 2026, 12:00 PM UTC
H
Humacyte V007 Phase 3 dialysis access trial results published
Humacyte (HUMA) announces that its V007 Phase 3 hemodialysis access trial results have been published in Lancet Digital Health.
EQUITY | Aug 19, 2026, 12:01 PM UTC
L
HUMA surgeon performs first commercial Symvess® implantation
HUMA says a board-certified vascular and endovascular surgeon performed the first commercial Symvess® implantation, describing the bioengineered blood vessel as a “revolutionary advancement.”
EQUITY | Aug 18, 2026, 12:00 PM UTC
L
Humacyte Announces Q2 2026 Financial Results
Humacyte announces second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 11:00 AM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC